uracil has been researched along with Weight Gain in 11 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Weight Gain: Increase in BODY WEIGHT over existing weight.
Excerpt | Relevance | Reference |
---|---|---|
"5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12." | 9.22 | Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016) |
"Adding alogliptin to previous insulin therapy (with or without metformin) significantly improved glycaemic control in patients with type 2 diabetes inadequately controlled on insulin, without causing weight gain or increasing the incidence of hypoglycaemia." | 9.14 | Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. ( Fleck, PR; Gross, JL; Mekki, Q; Rendell, MS; Rosenstock, J; Wilson, CA, 2009) |
"5% decrease from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12." | 5.22 | Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. ( Chaudhari, P; Del Prato, S; Fleck, P; Wilson, C, 2016) |
"Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain." | 5.17 | Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013) |
"Adding alogliptin to previous insulin therapy (with or without metformin) significantly improved glycaemic control in patients with type 2 diabetes inadequately controlled on insulin, without causing weight gain or increasing the incidence of hypoglycaemia." | 5.14 | Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. ( Fleck, PR; Gross, JL; Mekki, Q; Rendell, MS; Rosenstock, J; Wilson, CA, 2009) |
" Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain)." | 4.88 | DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. ( Scheen, AJ, 2012) |
"The EXAMINE trial included 5380 patients with T2D and a recent acute coronary syndrome, who were randomized to alogliptin or placebo." | 4.02 | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. ( Bakris, G; Ferreira, JP; Mehta, C; Rossignol, P; White, WB; Zannad, F, 2021) |
"Ecological evidence suggests that niacin (nicotinamide and nicotinic acid) fortification may be involved in the increased prevalence of obesity and type 2 diabetes, both of which are associated with insulin resistance and epigenetic changes." | 3.79 | Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. ( Cao, JM; Cao, Y; Gong, XJ; Guo, J; Guo, M; Li, D; Lun, YZ; Luo, N; Sun, WP; Tian, YJ; Zhou, SS, 2013) |
" Incidences of adverse effects were comparable between groups, with no relevant increases in hypoglycemia or weight gain seen." | 2.79 | Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. ( Kaku, K; Kanoo, T; Katou, M; Mori, M; Seino, Y, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Ferreira, JP | 1 |
Rossignol, P | 1 |
Bakris, G | 1 |
Mehta, C | 1 |
White, WB | 1 |
Zannad, F | 1 |
Sohn, JH | 1 |
Mutlu, B | 1 |
Latorre-Muro, P | 1 |
Liang, J | 1 |
Bennett, CF | 1 |
Sharabi, K | 1 |
Kantorovich, N | 1 |
Jedrychowski, M | 1 |
Gygi, SP | 1 |
Banks, AS | 1 |
Puigserver, P | 1 |
Rosenstock, J | 2 |
Wilson, C | 2 |
Fleck, P | 2 |
Li, D | 1 |
Tian, YJ | 1 |
Guo, J | 1 |
Sun, WP | 1 |
Lun, YZ | 1 |
Guo, M | 1 |
Luo, N | 1 |
Cao, Y | 1 |
Cao, JM | 1 |
Gong, XJ | 1 |
Zhou, SS | 1 |
Kaku, K | 1 |
Mori, M | 1 |
Kanoo, T | 1 |
Katou, M | 1 |
Seino, Y | 1 |
Del Prato, S | 1 |
Chaudhari, P | 1 |
Rendell, MS | 1 |
Gross, JL | 1 |
Fleck, PR | 1 |
Wilson, CA | 1 |
Mekki, Q | 1 |
Davidson, EP | 1 |
Coppey, LJ | 1 |
Dake, B | 1 |
Yorek, MA | 1 |
Scheen, AJ | 1 |
Kusunoki, Y | 1 |
Katsuno, T | 1 |
Myojin, M | 1 |
Miyakoshi, K | 1 |
Ikawa, T | 1 |
Matsuo, T | 1 |
Ochi, F | 1 |
Tokuda, M | 1 |
Murai, K | 1 |
Miuchi, M | 1 |
Hamaguchi, T | 1 |
Miyagawa, J | 1 |
Namba, M | 1 |
Giesecke, D | 1 |
Gallenmüller, P | 1 |
Tiemeyer, W | 1 |
Gropp, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan[NCT01521962] | Phase 3 | 67 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes[NCT00286429] | Phase 3 | 390 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The change between Body Weight measured at week 12 and Body Weight measured at baseline. (NCT00286429)
Timeframe: Baseline and Week 12.
Intervention | kg (Least Squares Mean) |
---|---|
Placebo | 0.50 |
Alogliptin 12.5 mg QD | 0.44 |
Alogliptin 25 mg QD | 0.31 |
The change between Body Weight measured at week 20 and Body Weight measured at baseline. (NCT00286429)
Timeframe: Baseline and Week 20.
Intervention | kg (Least Squares Mean) |
---|---|
Placebo | 0.73 |
Alogliptin 12.5 mg QD | 0.55 |
Alogliptin 25 mg QD | 0.45 |
The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | kg (Least Squares Mean) |
---|---|
Placebo | 0.63 |
Alogliptin 12.5 mg QD | 0.68 |
Alogliptin 25 mg QD | 0.60 |
The change between Body Weight measured at week 8 and Body Weight measured at baseline. (NCT00286429)
Timeframe: Baseline and Week 8.
Intervention | kg (Least Squares Mean) |
---|---|
Placebo | 0.39 |
Alogliptin 12.5 mg QD | 0.10 |
Alogliptin 25 mg QD | 0.18 |
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 12.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | 0.207 |
Alogliptin 12.5 mg QD | 0.333 |
Alogliptin 25 mg QD | 0.390 |
The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 16.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | 0.241 |
Alogliptin 12.5 mg QD | 0.319 |
Alogliptin 25 mg QD | 0.396 |
The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 20.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | 0.239 |
Alogliptin 12.5 mg QD | 0.318 |
Alogliptin 25 mg QD | 0.281 |
The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | -0.083 |
Alogliptin 12.5 mg QD | 0.199 |
Alogliptin 25 mg QD | 0.042 |
The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 4.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | -0.023 |
Alogliptin 12.5 mg QD | 0.132 |
Alogliptin 25 mg QD | 0.453 |
The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 8.
Intervention | ng/mL (Least Squares Mean) |
---|---|
Placebo | -0.024 |
Alogliptin 12.5 mg QD | 0.178 |
Alogliptin 25 mg QD | 0.348 |
The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 1.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 6.3 |
Alogliptin 12.5 mg QD | -5.0 |
Alogliptin 25 mg QD | -9.9 |
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 12.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | -1.4 |
Alogliptin 12.5 mg QD | -5.2 |
Alogliptin 25 mg QD | -2.9 |
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 16.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 4.6 |
Alogliptin 12.5 mg QD | -5.3 |
Alogliptin 25 mg QD | -6.3 |
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 2.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 1.0 |
Alogliptin 12.5 mg QD | -3.1 |
Alogliptin 25 mg QD | -11.4 |
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 20.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 8.6 |
Alogliptin 12.5 mg QD | -4.2 |
Alogliptin 25 mg QD | -11.3 |
The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 5.8 |
Alogliptin 12.5 mg QD | 2.3 |
Alogliptin 25 mg QD | -11.7 |
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 4.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 5.3 |
Alogliptin 12.5 mg QD | -5.0 |
Alogliptin 25 mg QD | -12.1 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 8.
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 5.4 |
Alogliptin 12.5 mg QD | -13.5 |
Alogliptin 25 mg QD | -14.1 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.13 |
Alogliptin 12.5 mg QD | -0.63 |
Alogliptin 25 mg QD | -0.71 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 12.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.27 |
Alogliptin 12.5 mg QD | -0.84 |
Alogliptin 25 mg QD | -0.81 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 16.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.22 |
Alogliptin 12.5 mg QD | -0.80 |
Alogliptin 25 mg QD | -0.76 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 20.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.17 |
Alogliptin 12.5 mg QD | -0.76 |
Alogliptin 25 mg QD | -0.74 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 4.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.26 |
Alogliptin 12.5 mg QD | -0.47 |
Alogliptin 25 mg QD | -0.58 |
The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline. (NCT00286429)
Timeframe: Baseline and Week 8.
Intervention | percentage of Glycosylated Hemoglobin (Least Squares Mean) |
---|---|
Placebo | -0.27 |
Alogliptin 12.5 mg QD | -0.76 |
Alogliptin 25 mg QD | -0.84 |
The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study. (NCT00286429)
Timeframe: 26 Weeks.
Intervention | participants (Number) |
---|---|
Placebo | 52 |
Alogliptin 12.5 mg QD | 27 |
Alogliptin 25 mg QD | 25 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 0 |
Alogliptin 12.5 mg QD | 3 |
Alogliptin 25 mg QD | 3 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 1 |
Alogliptin 12.5 mg QD | 11 |
Alogliptin 25 mg QD | 10 |
The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 5 |
Alogliptin 12.5 mg QD | 22 |
Alogliptin 25 mg QD | 33 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 40 |
Alogliptin 12.5 mg QD | 70 |
Alogliptin 25 mg QD | 70 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 17 |
Alogliptin 12.5 mg QD | 41 |
Alogliptin 25 mg QD | 47 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 6 |
Alogliptin 12.5 mg QD | 22 |
Alogliptin 25 mg QD | 23 |
The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study. (NCT00286429)
Timeframe: Baseline and Week 26.
Intervention | participants (Number) |
---|---|
Placebo | 0 |
Alogliptin 12.5 mg QD | 11 |
Alogliptin 25 mg QD | 11 |
The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study. (NCT00286429)
Timeframe: 26 Weeks.
Intervention | participants (Number) |
---|---|
Placebo | 105 |
Alogliptin 12.5 mg QD | 99 |
Alogliptin 25 mg QD | 86 |
1 review available for uracil and Weight Gain
Article | Year |
---|---|
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; | 2012 |
5 trials available for uracil and Weight Gain
5 other studies available for uracil and Weight Gain
Article | Year |
---|---|
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
Topics: Acute Coronary Syndrome; Aged; Body Mass Index; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2021 |
Liver mitochondrial cristae organizing protein MIC19 promotes energy expenditure and pedestrian locomotion by altering nucleotide metabolism.
Topics: Animals; Diet, High-Fat; Energy Metabolism; Liver; Mice; Mitochondria, Liver; Mitochondrial Proteins | 2023 |
Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats.
Topics: Animals; Betaine; Choline; CpG Islands; Dietary Supplements; DNA; DNA Damage; DNA Methylation; Epige | 2013 |
Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopa | 2011 |
[Effect of purine-rich nutrients on weight gain, catabolites in blood plasma and the uric acid transport of erythrocytes--a model study in dogs].
Topics: Allantoin; Animals; Biological Transport, Active; Dogs; Erythrocytes; Female; Purines; Uracil; Uric | 1990 |